CONCLUSIONS: Prior interventional therapy for BPH is associated with increased risks of urinary retention and incontinence after whole gland prostate cryoablation. Nevertheless, in properly selected patients, prior bladder outlet procedures are not an absolute contraindication to cryotherapy. Consideration should be given to management protocol in those men including but not limited to time for catheter removal postoperatively and continuing BPH medical treatment
INTRODUCTION AND OBJECTIVES: Radiofrequency ablation (RFA) using a bipolar coil design (EncageÔ device) which acts as a Faraday cage offer the versatility needed to perform focal treatment of localised prostate cancer whilst sparing critical anatomical and functional structures. We report preliminary outcomes of our ethics approved prospective development study investigating focal EncageÔ ablation (NCT02294903). Our primary objective was to determine the ablative efficacy 6 months after bipolar RFA. Secondary objectives included the assessment of genito-urinary toxicity.
METHODS: 21 men who had multi-parametric MR-visible index lesion concordant with transperineal biopsies and absence of clinically significant disease elsewhere with PSA </¼15ng/ml underwent daycase bipolar RFA with margins around the lesion of >/¼5mm using elastic image-fusion (SmartTargetÔ platform). mpMRI transperineal targeted biopsies of the ablated zone and any new suspicious areas were carried out at 6 months.
RESULTS: 20 men were treated,none were eligible for active surveillance. Data are available for 15 patients treated and followed up to 6 months. Patient characteristics are presented in Tab1. No significant residual disease was found in 13/15 patients. Two had clinically significant cancer of 6mm Gleason 7 (3+4) and 4mm Gleason 6, with one of these undergoing a retreatment. One harboured insignificant disease (1mm Gleason 6; pre-RFA 8 mm Gleason 7). Median PSA (IQR) at 6 months post RFA was 3.1 (1.2 to 4.8) ng/mL 2 patients showed decrease function in term of leakage (1 patient needed a urethral dilatation for stricture). For pad use, 3/15 patients started to use pad. IPSS changed from 9.2 to 8.9 and IPSS quality-of-life from 1.86 to 1.8. Across the 11 patients declaring in IIEF questionnaires some sexual stimulation, 2 patients with already poor erectile function had some decrease at the point to not be sufficient for penetrations. Erectile and bowel functions remained stable, as measured by the IIEF-15 and UCLA-EPIC bowel domain, respectively. EQ-5D and the FACT-P remained stable. There were 4 serious adverse events, none related to the procedure.
CONCLUSIONS: RFA using a bipolar device (EncageÔ) showed promising early disease control and a low profile of genitourinary toxicity. Trial completion to one-year follow-up is awaited and further phase II multicentre trials will be needed. METHODS: Prostate biopsies were collected from 10 very low risk prostate cancer patients (T1c, PSA density <0.15 ng / dL, Gleason 6, 2 cancer biopsy cores and 50% involvement any core with cancer) at diagnosis and 12 months after hemi-cryoablation. Cancer positive and negative lobes at diagnosis and the same areas 12 months after hemi-cryoablation (Diag+, Diag-, Cryo+ and Cryo-, respectively) were explored using immunohistochemistry for tumor infiltrating CD4+ T helper and CD8+ T cytotoxic cells (counted in 45 fields per patient with a 40x objective). The quantitative analysis of cells/mm 2 and CD8+/ CD4+ ratio were performed using ImageJ software.
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RESULTS: There was a significant increase in tumor infiltrating CD8+ T cytotoxic cells/mm 2 in post Cryo+ prostatic tissue (mean AE SD: 0.31 AE 0.30) compared to Diag+ (0.18 AE 0.15), p¼0.015. In contrast, tumor infiltrating CD4+ T helper cells/mm 2 showed a tendency to decrease in Cryo+ (0.26 AE 0.27) compared to Diag + (0.38 AE 0.52). Tumor infiltrating T cytotoxic / T helper cells ratio increased after hemicryoablation, with conceivable anti-tumor immunity and favorable prognosis.
CONCLUSIONS: This is the first study to show positive local immune modulation after prostate cancer cryoablation, characterized by increasing T cytotoxic / T helper cells ratio with potential to boost antitumor immune response. Long term follow-up and wider cohorts might e942 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 confirm potential clinical impact and if such modulation occurs for any ablation or for cryoablation only.
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MP70-20 PREDICTORS AND UTILIZATION OF ABLATIVE THERAPIES IN NEW YORK STATE
Maxwell B James*, Dennis J Robins, Wilson Sui, Ifeanyi C Onyeji, Justin T Matulay, Marissa C Theofanides, Sven Wenske, New York, NY INTRODUCTION AND OBJECTIVES: With the increased incidence of low-risk prostate and renal cancer, minimally invasive treatment options have become more desirable. In selected patients, focal ablative therapies offer less morbidity while achieving comparable outcomes to extirpative surgery. We describe patterns of usage of such therapies within a statewide database.
METHODS: We queried the New York Statewide Planning and Research Cooperative System database to identify patients who underwent any focal ablative treatment for prostate or renal malignancy from 2001 -2014 , ICD-9-CM procedure codes (5532-5535, 6096, 6097) , and ICD-9-CM diagnosis codes (185, 189.0, 189.1, 198.0) . Medical comorbidities are also available. Hospital specific characteristics were obtained using available information from the New York Department of Health and the American Hospital Association. High volume centers were defined as the five highest volume hospitals according to number of ablative procedures. Logistic regression was performed to determine independent predictors of utilization.
RESULTS: The final cohort included 1872 prostate ablations and 989 renal ablations. The five highest volume prostate and renal ablation centers performed 1173 (62.7%) and 376 (38.0%) cases, respectively. Demographic information is displayed in Table 1 . On multivariate analysis, treatment with prostate ablation was associated with black race (OR 0.27, 95%CI 0.19-0.39, p<0.001), increasing age (OR 0.98, 95%CI 0.967-0.998, p¼0.03), teaching hospital status (OR 3.32, 95%CI 2.34-4.71, p<0.001), and number of beds (OR 1.002, 95%CI 1.001-1.002, p<0.001). For renal ablation, significant predictors on multivariate analysis were black race (OR 0.46, 95%CI 0.25-0.84, p¼0.012), other non-white race (OR 0.48, 95%CI 0.29-0.79, p¼0.004), number of beds (OR 1.001, 95%CI 1.000-1.001, p<0.001), and higher Elixhauser comorbidity index (OR 1.017, 95%CI 1.002-1.033, p¼0.025).
CONCLUSIONS: In New York State, the use of ablative therapies is largely limited to academic institutions in urban areas, yet minority populations are significantly less likely to undergo such procedures. Future study should focus on identifying the barriers to treatment and what impact this might have on disease outcomes among different populations. Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e943
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